Drug · CHEMBL567
PERPHENAZINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PERPHENAZINE. Drugs and targets, record CHEMBL567. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL567
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Chlorpiprazine, Decentan, Fentazin, Perphenazine component of etrafon-a, Trilafon, Trilafon-la
- ChEMBL
- Open Targets' highest stage
- Approval, for 3 of its 10 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| DRD2 | D(2) dopamine receptor | Dopamine D2 receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/1813 |
Source ChEMBL
Diseases10
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
Source Open Targets
Trials22
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01157351 | 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated | Phase 4 | 450 | 2014-12-04 | perphenazine | Its name | ClinicalTrials.gov |
| NCT02431702 | A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform | Phase 3 | 337 | 2021-01-19 | perphenazine | Its name | ClinicalTrials.gov |
| NCT03019887 | Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction | 139 | 2021-09-09 | perphenazine | Its name | ClinicalTrials.gov | |
| NCT00806234 | Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics | Phase 4 | 127 | 2017-04-25 | perphenazine | Its name | ClinicalTrials.gov |
| NCT02199743 | Lurasidone Effects on Tissue Glutamate in Schizophrenia | Phase 4 | 35 | 2021-03-01 | perphenazine | Its name | ClinicalTrials.gov |
| NCT00802100 | Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia | Phase 4 | 21 | 2013-02-08 | perphenazine | Its name | ClinicalTrials.gov |
| NCT04606264 | Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data | Phase 3 | 3,395 | perphenazine | Its name | ClinicalTrials.gov | |
| NCT00014001 | CATIE- Schizophrenia Trial | Phase 4 | 1,600 | perphenazine | Its name | ClinicalTrials.gov | |
| NCT03510325 | Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT) | Phase 3 | 762 | perphenazine | Its name | ClinicalTrials.gov | |
| NCT02192723 | A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia | 550 | perphenazine | Its name | ClinicalTrials.gov |
1 to 10 of 22
See all 22 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Paliperidone Palmitate vs Oral Antipsychotics: serious adverse events | 42 of 226 | 53 of 218 | 444 | NCT01157351 | Trial comparisons |
| Lurasidone (LUR) vs NONLUR: serious adverse events | 1 of 14 | 0 of 8 | 22 | NCT02199743 | Trial comparisons |
Papers from its trials66
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Paced Visual Serial Addition Test | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL567
GET https://conductscience.org/api/drugs/v1/CHEMBL567/trials?page=2